story of the week
Teclistamab in Relapsed or Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Teclistamab in Relapsed or Refractory Multiple Myeloma
N. Engl. J. Med 2022 Jun 05;[EPub Ahead of Print], P Moreau, AL Garfall, NWCJ van de Donk, H Nahi, JF San-Miguel, A Oriol, AK Nooka, T Martin, L Rosinol, A Chari, L Karlin, L Benboubker, MV Mateos, N Bahlis, R Popat, B Besemer, J Martínez-López, S Sidana, M Delforge, L Pei, D Trancucci, R Verona, S Girgis, SXW Lin, Y Olyslager, M Jaffe, C Uhlar, T Stephenson, R Van Rampelbergh, A Banerjee, JD Goldberg, R Kobos, A Krishnan, SZ UsmaniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.